N4 Pharma creates DNA and RNA transfection technology using silica nanoparticles with an irregular surface, which traps and protects nucleic acid during its journey to cells.
Midatech’s gold nanoparticle (GNP) drug conjugate technology and recent acquisitions are helping transfer the firm into a speciality pharma company, an analyst says.
Researchers in Switzerland have devised a form of gold nanoparticle that shows promise as a weapon against tumours and as a delivery vehicle for drugs.
Abbott Laboratories has licensed Liquidia Technologies’ PRINT nanoparticle technology for the delivery of siRNA-based therapeutics, which have the potential to improve the company’s cancer portfolio.